112 related articles for article (PubMed ID: 8400329)
1. Pharmacokinetic/pharmacodynamic interactions of intensive cyclophosphamide, cisplatin, and BCNU in patients with breast cancer.
Jones RB; Matthes S; Dufton C; Bearman SI; Stemmer SM; Meyers S; Shpall EJ
Breast Cancer Res Treat; 1993; 26 Suppl():S11-7. PubMed ID: 8400329
[TBL] [Abstract][Full Text] [Related]
2. Cyclophosphamide, cisplatin, and carmustine: pharmacokinetics of carmustine following multiple alkylating-agent interactions.
Jones RB; Matthes S; Kemme D; Dufton C; Kernan S
Cancer Chemother Pharmacol; 1994; 35(1):59-63. PubMed ID: 7987978
[TBL] [Abstract][Full Text] [Related]
3. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine.
Jones RB; Matthes S; Shpall EJ; Fisher JH; Stemmer SM; Dufton C; Stephens JK; Bearman SI
J Natl Cancer Inst; 1993 Apr; 85(8):640-7. PubMed ID: 8468721
[TBL] [Abstract][Full Text] [Related]
4. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics.
Cagnoni PJ; Matthes S; Day TC; Bearman SI; Shpall EJ; Jones RB
Bone Marrow Transplant; 1999 Jul; 24(1):1-4. PubMed ID: 10435726
[TBL] [Abstract][Full Text] [Related]
5. Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer.
Petros WP; Broadwater G; Berry D; Jones RB; Vredenburgh JJ; Gilbert CJ; Gibbs JP; Colvin OM; Peters WP
Clin Cancer Res; 2002 Mar; 8(3):698-705. PubMed ID: 11895898
[TBL] [Abstract][Full Text] [Related]
6. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.
Peters WP; Ross M; Vredenburgh JJ; Meisenberg B; Marks LB; Winer E; Kurtzberg J; Bast RC; Jones R; Shpall E
J Clin Oncol; 1993 Jun; 11(6):1132-43. PubMed ID: 8501500
[TBL] [Abstract][Full Text] [Related]
7. High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes.
Bearman SI; Overmoyer BA; Bolwell BJ; Taylor CW; Shpall EJ; Cagnoni PJ; Mechling BE; Ronk B; Barón AE; Purdy MH; Ross M; Jones RB
Bone Marrow Transplant; 1997 Dec; 20(11):931-7. PubMed ID: 9422471
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer.
Gilbert CJ; Petros WP; Vredenburgh J; Hussein A; Ross M; Rubin P; Fehdrau R; Cavanaugh C; Berry D; McKinstry C; Peters WP
Cancer Chemother Pharmacol; 1998; 42(6):497-503. PubMed ID: 9788577
[TBL] [Abstract][Full Text] [Related]
9. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease.
Reece DE; Nevill TJ; Sayegh A; Spinelli JJ; Brockington DA; Barnett MJ; Klingemann HG; Connors JM; Nantel SH; Shepherd JD; Sutherland HJ; Voss NJ; Fairey RN; O'Reilly SE; Phillips GL
Bone Marrow Transplant; 1999 Jun; 23(11):1131-8. PubMed ID: 10382952
[TBL] [Abstract][Full Text] [Related]
10. Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer.
Nieto Y; Cagnoni PJ; Bearman SI; Shpall EJ; Matthes S; Jones RB
Biol Blood Marrow Transplant; 2000; 6(2A):198-203. PubMed ID: 10816028
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment.
Chap L; Shpiner R; Levine M; Norton L; Lill M; Glaspy J
Bone Marrow Transplant; 1997 Dec; 20(12):1063-7. PubMed ID: 9466279
[TBL] [Abstract][Full Text] [Related]
12. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.
Peppercorn J; Herndon J; Kornblith AB; Peters W; Ahles T; Vredenburgh J; Schwartz G; Shpall E; Hurd DD; Holland J; Winer E
Cancer; 2005 Oct; 104(8):1580-9. PubMed ID: 16118805
[TBL] [Abstract][Full Text] [Related]
13. Positive selection and ex vivo expansion of hematopoietic progenitors as autografts for high-dose chemotherapy, potential importance in patients with bone metastases.
Purdy MH
Can J Oncol; 1995 Dec; 5 Suppl 1():63-8. PubMed ID: 8853528
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and immediate effects of high-dose carmustine in man.
Henner WD; Peters WP; Eder JP; Antman K; Schnipper L; Frei E
Cancer Treat Rep; 1986 Jul; 70(7):877-80. PubMed ID: 3719578
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects.
Jones RB; Stockerl-Goldstein KE; Klein J; Murphy J; Blume KG; Dansey R; Martinez C; Matthes S; Nieto Y
Biol Blood Marrow Transplant; 2004 Apr; 10(4):276-82. PubMed ID: 15077226
[TBL] [Abstract][Full Text] [Related]
16. High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial.
Stemmer SM; Cagnoni PJ; Shpall EJ; Bearman SI; Matthes S; Dufton C; Day T; Taffs S; Hami L; Martinez C; Purdy MH; Arron J; Jones RB
J Clin Oncol; 1996 May; 14(5):1463-72. PubMed ID: 8622060
[TBL] [Abstract][Full Text] [Related]
17. Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Nieto Y; Xu X; Cagnoni PJ; Matthes S; Shpall EJ; Bearman SI; Murphy J; Jones RB
Clin Cancer Res; 1999 Apr; 5(4):747-51. PubMed ID: 10213208
[TBL] [Abstract][Full Text] [Related]
18. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials.
Buckner JC; Ballman KV; Michalak JC; Burton GV; Cascino TL; Schomberg PJ; Hawkins RB; Scheithauer BW; Sandler HM; Marks RS; O'Fallon JR; ;
J Clin Oncol; 2006 Aug; 24(24):3871-9. PubMed ID: 16921039
[TBL] [Abstract][Full Text] [Related]
19. High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial.
Peters WP; Eder JP; Henner WD; Schryber S; Wilmore D; Finberg R; Schoenfeld D; Bast R; Gargone B; Antman K
J Clin Oncol; 1986 May; 4(5):646-54. PubMed ID: 3517240
[TBL] [Abstract][Full Text] [Related]
20. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer.
Eder JP; Antman K; Peters W; Henner WD; Elias A; Shea T; Schryber S; Andersen J; Come S; Schnipper L
J Clin Oncol; 1986 Nov; 4(11):1592-7. PubMed ID: 3534155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
